ABSCF (AB Science) LT-Debt-to-Total-Asset: 0.76 (As of Dec. 2025)

What is AB Science LT-Debt-to-Total-Asset?

AB Science ABSCF 62 LT-Debt-to-Total-Asset is 0.76 as of Dec. 2025. GuruFocus rates ABSCF with a GF Score™ of 62/100 and a GF Value™ of $1.39 (Modestly Undervalued). The stock has 11 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AB Science's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.76.

AB Science's long-term debt to total assets ratio increased from Dec. 2024 (0.63) to Dec. 2025 (0.76). It may suggest that AB Science is progressively becoming more dependent on debt to grow their business.

AB Science (OTCPK:ABSCF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AB Science LT-Debt-to-Total-Asset Related Terms

AB Science LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for AB Science's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AB Science LT-Debt-to-Total-Asset Chart

AB Science Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.36

0.81

0.67

0.63

0.76

AB Science Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.67	0.74	0.63	0.76	0.76

62GF Score

AB Science ABSCF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AB Science LT-Debt-to-Total-Asset Calculation

AB Science's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	21.847	/	28.718
	=	0.76

AB Science's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	21.847	/	28.718
	=	0.76

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.76 mean?

AB Science (ABSCF) has a LT-Debt-to-Total-Asset of 0.76 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AB Science and its competitors.

Is AB Science's LT-Debt-to-Total-Asset too high?

AB Science's current LT-Debt-to-Total-Asset is 0.76. Overall, AB Science has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does AB Science's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

AB Science's LT-Debt-to-Total-Asset of 0.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AB Science and its competitors. AB Science's current LT-Debt-to-Total-Asset is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AB Science stock overvalued right now?

Based on GuruFocus' analysis, AB Science (ABSCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.39, compared to a current price of $1.12 — trading 19.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.76. AB Science's overall GF Score™ is 62/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For AB Science (ABSCF), the current LT-Debt-to-Total-Asset is 0.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AB Science (ABSCF) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of $1.12 is trading 19.4% below its estimated GF Value™ of $1.39. GuruFocus considers AB Science to be Modestly Undervalued.

Key valuation signals for ABSCF:

LT-Debt-to-Total-Asset: 0.76
GF Value™: $1.39 vs. price of $1.12 (19.4% below fair value)
GF Score™: 62/100 with 11 warning signs

No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XPAR:EAPI XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506 XPAR:IPN TSE:4507

Other Exchanges 0Q77:UK AB:France A8D:Germany

Address 3, Avenue George V, Paris, FRA, 75008

Website https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.

62GF Score

Get the complete analysis for ABSCF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12

Price

$1.39

GF Value

View ABSCF Analysis

See LT-Debt-to-Total-Asset data for all stocks →